Lexeo Therapeutics, Inc. Logo

Lexeo Therapeutics, Inc.

Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.

LXEO | US

Overview

Corporate Details

ISIN(s):
US52886X1072
LEI:
Country:
United States of America
Address:
345 PARK AVENUE SOUTH, 10010 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing curative treatments for genetically defined diseases. The company advances a pipeline of investigational AAV-mediated gene therapies, with a primary focus on genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease. Building on foundational research from Weill Cornell Medicine and the University of California San Diego, Lexeo's strategy prioritizes efficient development, advanced manufacturing, and strategic partnerships with leading research institutions to develop high-impact therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Lexeo Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Lexeo Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Lexeo Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM
Vera Therapeutics, Inc. Logo
Developing biologic therapies for serious immunological diseases, focusing on IgA Nephropathy.
United States of America
VERA
Vericel Corp Logo
Develops autologous cell therapies for sports medicine and severe burn care markets.
United States of America
VCEL
Verona Pharma plc Logo
Develops innovative therapies for chronic respiratory diseases like COPD and asthma.
United States of America
VRNA
Verrica Pharmaceuticals Inc. Logo
Develops topical therapies for skin diseases like molluscum contagiosum and common warts.
United States of America
VRCA
VERTEX PHARMACEUTICALS INC / MA Logo
Develops transformative medicines for serious diseases, specializing in cystic fibrosis.
United States of America
VRTX
VERU INC. Logo
Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.
United States of America
VERU
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France
VETO
Viatris Inc Logo
A global healthcare company distributing branded and generic medicines in over 165 countries.
United States of America
VTRS
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland
VIFN

Talk to a Data Expert

Have a question? We'll get back to you promptly.